Andrea Visentin, MD, PhD, University of Padua, Padova, Italy, discusses the association between immunoglobulin A (IgA) during ibrutinib therapy and rates of infection in patients with chronic lymphocytic leukemia (CLL). Dr Visentin gives an overview of the rationale for this investigation and reports that IgA levels increases during ibrutinib therapy and is subsequently associated with a shorter risk to infection after the first year of ibrutinib therapy. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.